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Summary
Background: Certain types of Human Papillomavirus (HPV) are highly associated with
cervical cancer and precursor lesions (dysplasia), but the distribution of HPVs in
Northern Canada is largely unknown. This study determined the prevalences of HPV
infection due to different virus types and the association of different virus types
in the Northwest Territories (NWT).with cervical dysplasia
Methods: Between April 2008 and March 2009, women who underwent routine Pap
testing in the NWT were included in the study. An in-house Luminex assay detected
type-speciﬁc HPV infections. The HPV prevalence rates and population attributable
risk fractions were calculated.
 This study was ﬁnancially supported by the Government of Canada International Polar Year Program and the Public Health
gency of Canada. P. Brassard was supported by a clinician scientist career award from the Fonds de la Recherche en Santé
u Quebec (FRSQ).
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Results: In 5725 bio-samples, the overall HPV prevalence was 24.2%, and of the
HPV-positive samples, 76.6% harbored high-risk types, 35.2% harbored multi-type
infections, and 21.6% harbored HPV16 or 18 infections. The HPV prevalence was
approximately 50% higher among Aboriginal than non-Aboriginal women. The age-
speciﬁc HPV prevalence exhibited a U-shape distribution in the Aboriginal group. The
prevalence of HPV16 or 18 infections found in high-grade lesions was 34.1%. Among
this study population, 89.5% of the cases with cervical dysplasia were attributable to
HPV infection, with 27.1% attributable to HPV16/18.
Conclusion: The high prevalence of high-risk HPV in this population, particularly in
the Aboriginal group, will require further studies to identify speciﬁc predictors of
Published by Elsevier Ltd. All rights reserved.
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Cytological reports were issued according to the
Bethesda system [13,14]. Pap test results wereinfection.
Crown Copyright © 2011
Introduction
In Canada, approximately 1300 new cervical can-
cer cases are diagnosed each year [1]. Aboriginal
groups experience a higher incidence and mortality
of cervical cancer than non-Aboriginal groups [2].
Among Inuit women, the age-standardized cervical
cancer incidence rate is 14.7 per 100,000, which is
3 times higher than that in the general Canadian
population [3]. Aboriginal groups account for more
than half the population of the Northwest Territo-
ries (NWT) [4]. An increased risk of cervical cancer
has been consistently observed in various regions
across Northern Canada [5,6].
Human Papillomavirus (HPV) is a sexually trans-
mitted virus, and persistent infection with speciﬁc
types of this virus appears to be a necessary step
in the development of invasive cervical cancer and
precursor lesions [7,8]. HPV is detected in almost
100% of women with invasive cervical cancer [9].
Moreover, women who test positive for HPV and lack
cervical lesions are at increased risk for developing
precursor lesions and subsequent cervical cancer
[10,11].
To date, limited data have been available on
the distributions and health consequences of HPV
infections in Canada, particularly in the Northern
populations. This research was designed to esti-
mate the prevalence of HPV infections by type in
the pre-vaccination era and to assess the asso-
ciation between type-speciﬁc HPV infection and
cervical dysplasia in the NWT.
Methods
Study populationThis cross-sectional design consisted of all women
aged 14 years or older presenting for a regu-
larly scheduled or initial Papanicolaou (Pap) smear
c
c
(
(xamination in the NWT between April 2008 and
arch 2009. All women were included in the study
nless they chose to opt out at the time of their
ap smear. If more than one Pap smear was per-
ormed over the study period, only the ﬁrst sample
as kept for analysis. Universal health care is pro-
ided in the NWT; thus, there are no other Pap
est providers in the area. In 2008, 88% of women
ged 18—69 in the NWT reported having had a
ap test in the previous three years [12]. This
tudy was announced publically by local media out-
ets, and further information was made available
t the NWT Department of Health and Social Ser-
ices. A research license was obtained from the
urora Research Institute to perform the study.
thics approval came from the Health Canada Ethics
eview Board, McGill University, and Stanton Terri-
orial Health Authority.
pecimen collection and preparation
amples were collected through liquid-based cervi-
al scrapes, stored in the NWT regional laboratory,
nd shipped to the DynaLife Diagnostics Labora-
ory in Edmonton, Canada. Approximately half of
he medium was retained for Pap testing. The
emainder was shipped to the National Microbiol-
gy Laboratory (NML) in Winnipeg, Canada, for HPV
yping. Cervical cytology and HPV testing were per-
ormed independently in a blinded fashion to ensure
he elimination of reporter bias.
ap smear testinglassiﬁed as normal (including benign), atypi-
al squamous cells of undetermined signiﬁcance
ASCUS), low-grade squamous intraepithelial lesion
LSIL), and high-grade squamous intraepithelial
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(PAR). In calculating the PAR, to avoid duplicate
counting of those infected with both HR and LR, the
exposed population was ﬁrst stratiﬁed into those
infected with only HR, only LR, and both. The PARs
were then summed across the strata [24].
Results
No women asked to opt out from the study. A total
of 5725 liquid cytology samples were collected and
tested. This sample represents 35% of women aged
14—85 in the NWT. The mean and median ages of
participants were 35.3 and 33.0, respectively.
HPV prevalence
HPV DNA was detected in 24.2% of subjects
(n = 1383/5725) with a range from 11.0% and 49.2%
in various age groups. All 45 types were detected
(Table 1). The most common HPV types detected
were HPV16 (4.1%), HPV31 (2.1%), HPV66 (1.9%),
HPV39 (1.6%), HPV51 (1.6%), and HPV62 (1.6%).
Among HPV-infected women, 76.6% had an HR-
type infection, 35.2% had HPV m infections, and
21.6% had HPV16/18. The overall prevalences of
HPV m, HR s, HR m, and LR s were 8.5%, 11.1%,
5.1%, and 4.6%, respectively. Fig. 1 shows the age
distribution of HPV types. Both HR and HPV16/18
were most prevalent in women under age 30,
with decreasing prevalence observed up to the
40—49 age group. In this study, 49.5% of women
were non-Aboriginal (2834/5725), and 50.5% were
Aboriginal (2891/5725) (Table 2). The HPV preva-
lence was higher in Aboriginal than non-Aboriginal
women in each age group, in particular among
women aged 60 or over. It is of note that the
prevalence of HPV increased again after age 50
in Aboriginal women, but there was no increase
with age in non-Aboriginal women. Using the NWT
2008 population [4] as the standard, the age-
adjusted prevalence rate in the Aboriginal group
(28.0%, 95% CI: 25.9, 30.0) was higher than in the
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esion (HSIL). Samples with atypical squamous cells
ASCH) for which HSIL could not be excluded were
dded to the HSIL category.
PV typing
he Luminex assay is an in-house method devel-
ped at the NML in Canada that detects 45 HPV
ypes. These include 23 of the 25 IARC high-risk
HR) types found in groups 1, 2a, and 2b (HPV16,
8, 26, 30, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58,
9, 66, 67, 68, 69, 70, 73, 82 and 85) [15] and 22
ypes considered to be low (LR) or unknown risk
6, 11, 13, 32, 40, 42, 43, 44, 54, 61, 62, 71, 72,
4, 81, 83, 84, 86, 87, 89, 90, and 91). Brieﬂy,
amples in SurePath® (BD Diagnostics) liquid-based
ytology medium were centrifuged, and the cell
ellet was extracted using a MagNA Pure automated
nstrument (Roche). The DNA was ampliﬁed with a
ested PCR method using the general PGMY primer
et for the ﬁrst round [16] and the GP5+/GP6+
rimer set for the second round [17]. This method
mpliﬁes a fragment of the L1 region of the HPV
enome (approximately 150 bp in length). HPV DNA
as detected and typed by hybridization to micro-
pheres coupled to speciﬁc probes for 45 HPV types
ccording to the methods for Luminex xMAP tech-
ology [18]. The speciﬁcity and sensitivity of this
ethod for all 45 types of HPV were measured using
loned HPV DNAs. Comparison with the linear array
Roche) [19] and other HPV genotyping kits [20]
howed that this Luminex assay is comparable to
ther commercial genotyping methods.
easurement and analysis methods
ap test results, HPV types and demographic
nformation were linked for analysis. Cases were
xcluded if their ages were unknown (113 cases).
dditionally, 14 samples with unknown cytological
esults were excluded from the cytology analysis.
PV s and HR s were cases with only a single type
f HPV infection and cases with only a single type
f HR-HPV infection, respectively. However, sam-
les in which two or more HPV types were detected
HPV m) were counted as positive for each type in
alculations of type-speciﬁc prevalence. In addi-
ion, HR m was deﬁned as samples with two or more
ypes of HR-HPV infection.
The prevalence values for type-speciﬁc HPV
nfections including species and cervical dysplasia
ere calculated with 95% conﬁdence intervals (CI)
21—23].
The number of cervical dysplasias (LGSIL +HGSIL)
ssociated with HPV infection in the NWT was mea-
ured using the population attributable risk fraction
Age Group
Figure 1 Prevalence of HPV types by age group,
2008—2009, NWT, Canada.
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Table 1 HPV type distribution according to cytological results 2008—2009, NWT, Canada.a
HPV alpha-papillomavirus speciesb Cytological results Total
Normal ASCUS LSIL HSIL ASCH n %
HPV negative 4291 25 11 1 0 4328 75.8
HPV positive 1128 115 97 20 23 1383 24.2
HR-HPV
16 177 21 21 8 6 233 4.1
31 86 17 9 1 5 118 2.1
66 74 14 18 106 1.9
39 68 11 9 1 2 91 1.6
51 63 7 17 2 89 1.6
45 63 13 9 2 87 1.5
52 59 10 3 3 4 79 1.4
58 52 8 7 3 6 76 1.3
18 49 17 9 0 1 76 1.3
67 58 6 6 0 3 73 1.3
59 59 5 5 1 1 71 1.2
70 51 5 8 1 65 1.1
56 38 4 16 58 1.0
33 35 2 2 1 40 0.7
35 29 4 3 3 1 40 0.7
73 24 1 3 28 0.5
53 20 1 6 27 0.5
68 12 2 3 1 18 0.3
69 13 2 3 18 0.3
85 13 2 1 16 0.3
82 7 2 4 13 0.2
30 9 3 1 13 0.2
26 1 1 2 0.0
Total 1060 158 163 24 32 1437 25.2
LR-HPV
62 85 2 3 90 1.6
42 70 2 3 2 77 1.3
89 49 4 3 56 1.0
6 40 7 7 54 0.9
54 42 1 3 46 0.8
81 36 1 4 41 0.7
83 35 2 2 39 0.7
74 36 3 39 0.7
72 36 1 1 38 0.7
40 26 3 2 31 0.5
90 20 1 4 25 0.4
84 19 3 22 0.4
86 18 2 20 0.4
44 19 19 0.3
11 11 6 1 18 0.3
43 6 1 2 9 0.2
13 4 2 1 7 0.1
32 6 6 0.1
87 5 1 6 0.1
91 1 1 4 6 0.1
61 4 4 0.1
71 1 1 0.0
Total 569 41 41 0 3 654 11.5
a HPV types 2, 3, 7, 10, 27, 28, 29, 34, 57, 78, and 94 are not detected with the Luminex assay. Moreover, 14 samples with
unknown Pap test results were not included.
b Each patient could have a maximum of 6 types of HPV infection.
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Table 2 HPV prevalence (%) by age group among Aboriginal and non-Aboriginal women in the NWT, Canada,
2008—2009.
Age group Total Na Any type HR type LR type HPV m HR m HPV16/18
Aboriginal
14—19 394 55.8 48.0 7.9 27.7 19.0 14.5
20—29 936 39.4 31.3 8.1 14.3 9.5 8.7
30—39 645 18.0 11.2 6.8 5.0 1.9 1.7
40—49 479 12.5 7.9 4.6 3.8 1.3 1.7
50—59 277 22.0 15.2 6.9 5.8 1.4 3.2
≥60 103 26.2 18.4 7.8 8.7 2.9 1.9
Total 2834 30.1 23.0 7.1 11.2 6.7 5.9
Non-Aboriginal
14—19 163 33.7 26.4 7.4 12.9 11.0 10.4
20—29 752 32.7 27.1 5.6 12.0 7.2 10.2
30—39 800 15.4 11.1 4.3 3.9 2.6 3.4
40—49 643 9.8 6.2 3.6 2.5 1.1 1.2
50—59 427 8.9 6.3 2.6 1.6 0.7 0.7
≥60 106 8.5 5.7 2.8 3.8 1.9 0
Total 2891 18.5 14.1 4.3 5.8 3.6 4.6
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ia Total samples in this age group.
on-Aboriginal group (18.8%, 95% CI: 17.0, 20.5).
he prevalence of any HPV type and of HR types
iffered signiﬁcantly between Aboriginal and non-
boriginal women among those aged 14—19, 50—59,
nd 60 and over.
revalence by Pap test results
pproximately 5% of the Pap test results were
bnormal. Among women with normal Pap test
esults (n = 5419), 20.8% had an HPV infection, com-
ared with 92.1% of women with dysplasia (LSIL
r HSIL n = 152). HPV16/18 was present in 4.2% of
t
s
A
(
Table 3a Cytological results by HPV types for Aboriginal st
Cytology Overall Any type HR-HPV
N % N % N %
Age < 30
Normal 1190 89.7 465 39.1 371 31.2
ASCUS 69 5.2 59 85.5 50 72.5
LSIL 51 3.8 47 92.2 44 86.3
HSIL 17 1.3 16 94.1 16 94.1
Total 1327 1.0 587 44.2 481 36.2 1
Age≥ 30
Normal 1473 98.1 237 16.1 144 9.8
ASCUS 13 0.9 10 76.9 10 76.9
LSIL 8 0.5 8 100.0 8 100.0
HSIL 8 0.5 8 100.0 8 100.0
Total 1502 1.0 263 17.5 170 11.3he cytologically normal samples, 27.8% of the LSIL
nd 34.1% of the HSIL samples. Among women with
n abnormal Pap test, the highest percentage with
n HPV infection was in the age group 14—19, fol-
owed by ages 20—29. Tables 3a and 3b depict HPV
ypes by cytological result among women aged <30
nd aged ≥30 among Aboriginal and non-Aboriginal
omen. The prevalences of HR-HPV and HPV16/18
ncreased with the level of cervical abnormali-
ies in all groups. The prevalence of HPV16/18 in
amples with normal cytology was higher in the
boriginal group than in the non-Aboriginal group
5.1% vs. 3.1%). However, HPV16/18 was found less
atus, in the NWT, Canada, 2008—2009.
LR-HPV HPV m HR m HPV16/18
N % N % N % N %
94 7.9 177 14.9 89 7.5 111 9.3
9 13.0 27 39.1 13 18.8 16 23.2
3 5.9 32 62.7 15 29.4 9 17.6
0 0.0 5 29.4 4 23.5 2 11.8
06 8.0 241 18.2 121 9.1 138 10.4
93 6.3 61 4.1 7 0.5 25 1.7
0 0.0 6 46.2 4 30.8 1 7.7
0 0.0 5 62.5 3 37.5 1 12.5
0 0.0 2 25.0 2 25.0 3 37.5
93 6.2 74 4.9 16 1.1 30 2.0
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Table 3b Cytological results by HPV types for non-Aboriginal status, in the NWT, Canada, 2008—2009.
Cytology Overall Any type HR-HPV LR-HPV HPV m HR m HPV16/18
N % N % N % N % N % N % N %
Age < 30
Normal 832 91.0 231 27.8 179 21.5 52 6.3 76 9.1 28 3.4 58 7.0
ASCUS 40 4.4 33 82.5 32 80.0 1 2.5 15 37.5 11 27.5 18 45.0
LSIL 32 3.5 27 84.4 26 81.3 1 3.1 17 53.1 11 34.4 12 37.5
HSIL 10 1.1 10 100.0 10 100.0 0 0.0 3 30.0 3 30.0 6 60.0
Total 914 1.0 301 32.9 247 27.0 54 5.9 111 12.1 53 5.8 94 10.3
Age≥ 30
Normal 1924 97.8 195 10.1 128 6.7 67 3.5 44 2.3 20 1.0 28 1.5
ASCUS 18 0.9 13 72.2 12 66.7 1 5.6 6 33.3 4 22.2 1 5.6
LSIL 17 0.9 15 88.2 13 76.5 2 11.8 5 29.4 3 17.6 5 29.4
HSIL 9 0.5 9 100.0 8 88.9 1 11.1 3 33.3 3 33.3 4 44.4
Total 1968 1.0 232 11.8 161 8.2 71 3.6 58 2.9 30 1.5 38 1.9
Table 4 Population attributable risk of cervical abnormality to HPV infection, NWT, Canada, 2008—2009.
HPV infection Pap test results PAR%
Normal LSIL/HSIL
HPV negative 4291 12
Any type 1128 140 89.5
Single-HR 518 63 40.3
Single-LR 252 5 2.7
Multiple-HR 144 44 28.6
Multiple-LR 54 2 1.2
HR/LR mix 160 26 16.6
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frequently at all levels of abnormal cytology among
Aboriginal women, especially in the <30-year-old
age group.
Preventable fractions for cervical
abnormalities
HPV infection accounted for 89.5% of the cervical
abnormalities found in this population, with 40.3%
attributable to a single HR-HPV infection and 27.1%
attributable to HPV16/18 infection (Table 4).
Discussion
This study was a population-based study using rou-
tine Pap test samples. Our study covered 35% of
the targeted population of women of the same age
group and thus may be considered a valid sample for
conducting population impact analysis in the NWT.
r
g
o42 27.1
The HPV prevalences in both the Aboriginal
30.1%) and non-Aboriginal women (18.5%) in this
tudy were slightly higher than those found in other
tudies of Aboriginal [25,26] and non-Aboriginal
27,28] populations in Canada performed using sim-
lar HPV-detection methods. The proportion of HR
ypes among the HPV-positive women was lower
han those found in British Colombia and Ontario
ut higher than that found in Quebec [26—28].
imilar to most European studies, the two most
ommon HPV types detected in NWT were HPV16
nd 31 [29—32]. The HPV16/18 prevalence in the
WT was lower than that observed in all similar
tudies in Canada [26—28] but was comparable to
he prevalences observed in studies in Europe and
he US [31,33—35]. Several HR-HPV types other than
PV16/18, such as HPV31, 66, 39, 51 and 62, are
elatively common in the NWT.The assessment of HPV prevalence by age group
evealed a higher prevalence in the younger age
roups, which is consistent with the results of
ther studies [27,28,36,37]. This ﬁnding conﬁrms
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hat is already known about the natural history
f HPV infection, which is characterized by higher
nfection rates after sexual initiation. In agree-
ent with published data [26,38], the age-adjusted
PV prevalence rate in the Aboriginal group was
igher than that in the non-Aboriginal group in
he same area. A U-shaped age-speciﬁc HPV preva-
ence distribution observed for Aboriginal but not
or non-Aboriginal women in the NWT has been
bserved elsewhere in Canada [25—28]. Studies
rom Costa Rica and other Latin American countries
39,40] have also shown a U-shaped distribution
f age-speciﬁc prevalence rates, with the lowest
revalence among the 40- to 49-year-old age group.
his result differs from those of most European
tudies, which, with the exception of a study con-
ucted in the former Soviet Union [30], report a
ecreased prevalence after age 20 and a leveling
ff after age 45 [31,34,35,40]. Our study group
s currently exploring the social factors and other
ifestyle factors that may play an important role in
xplaining this age distribution among the Aborigi-
al population.
The Pap test abnormality rate in this study
as similar to that found in other studies [26,27].
mong women with a normal Pap test, the HPV
revalence was higher in those younger than 30
han in older women, whereas in the group with
SIL, the HPV prevalence was higher in women aged
0 years and older. This result reﬂects the fact that
PV infection is common in young women and is
ost often transient, but persistent HPV infection
s associated with cervical dysplasia [41]. Women
ged 30 years and older with ASCUS lesions have
een identiﬁed as the group most likely to beneﬁt
rom triage by HPV DNA testing before being eval-
ated with a colposcopy because this population
xperienced higher rates of non-transient, clini-
ally signiﬁcant infection than the overall female
opulation [42—44]. In our study with ASCUS cytol-
gy, 71.0% of women aged over 30 were infected
ith HR types, whereas 75.2% of women aged 30 or
ounger were infected with HR-HPV. This percent-
ge is higher than the 53% HR-HPV infection rate
eported in all ASCUS lesions from another recent
tudy in a Canadian Aboriginal group using a simi-
ar HPV-detection technique [26]. In this study, 2.4%
f the all cytology results were classiﬁed as ASCUS
ompared with 3.3% in the Nunavik study. As the
roportions of ASCUS cytology reports were simi-
ar in both study groups, with similar HPV detection
nd classiﬁcationmethods, the observed rate of HR-
PV infection seems to reﬂect the actual infection
ate in the NWT.
Due to the relatively high prevalence of HR-HPV
n ASCUS lesions in the >30 years old population,225
egardless of Aboriginal status, ASCUS triage may
ot be cost effective in the NWT because it
ould result in a high colposcopy workload. Fur-
her studies should focus on this speciﬁc clinical
anagement issue.
The PAR for multiple factors in multi-factorial
isease can be overestimated because a simple
umming of PARs for single factors ignores multi-
le risk factors in individual cases, thereby counting
hese cases more than once in the calculations.
he stratiﬁcation approach in the current analy-
is, whereby the PAR was calculated separately for
R, LR and both and then summed across strata,
revents inﬂation of the overall PAR. This baseline
ata may help policy makers estimate the poten-
ial impact of vaccination on planned screening
ctivities using HPV tests, especially in terms of
redictive values and the frequency of testing.
There are potential limitations of this study.
irst, no single PCR protocol is ideal for the detec-
ion all types of HPV. All of the above comparisons
f the prevalence rates should be considered with
ome caution because we used the most recent IARC
lassiﬁcation for HR-HPV and a novel (Luminex)
etection method, which is as sensitive as linear
rrays but is able to detect more types than other
reviously reported technologies such as GP5+/6+,
LISA, or hybrid capture [19,20]. Second, due to
ample-size constraints, the effects of multiple
irus exposures were not investigated in detail.
In conclusion, the relatively high prevalence of
R-HPV in this population, especially in the Aborig-
nal group, will require further studies to explore
peciﬁc predictors of infection.
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